Biospring Partners
Biospring Partners is a New York-based growth buyout firm that invests in technology-enabled, EBITDA-positive pharma services businesses across outsourced biomanufacturing and clinical trial services.
- Company typePrivate
- Founded2020
- HeadquartersNew York, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Biospring Partners does
Biospring Partners is a New York-based private growth buyout firm founded in 2020 that invests exclusively in technology-enabled, EBITDA-positive B2B pharma services businesses. The firm concentrates on two primary investment themes: outsourced complex biomanufacturing (encompassing biologics, antibody-drug conjugates, cell and gene therapy manufacturing) and outsourced clinical trial services (including clinical trial site networks, digital pathology, and direct-to-patient platforms), with a third digital transformation overlay. Its portfolio comprises Abzena (a global biologics and ADC CDMO), Kiniciti (a Cell and Gene Therapy aggregator co-founded with Welsh, Carson, Anderson & Stowe), Cedar Health Research and CenExel (clinical trial site networks), PathAI (AI-powered digital pathology, subject to a pending Roche acquisition announced May 2026 for $750M plus up to $300M in milestones), Labviva (lab procurement marketplace), and ixlayer (direct-to-patient platform).
The firm applies a hands-on value creation approach that combines a proprietary sourcing platform, deep thematic research, and an experienced operating team staffed by former pharma executives (notably ex-GSK and Operation Warp Speed senior leadership) and PE/VC operators with backgrounds at General Atlantic, Francisco Partners, NFX, and Health Velocity Capital. Distribution occurs through direct, relationship-based engagement with pharma services management teams and co-investor partners, supported by content marketing (website news section, webinars, industry primers).
Biospring's revenue model follows standard private equity fund management mechanics: it earns management fees on committed or invested capital from limited partners and carried interest on fund returns. Headcount is stated at 11–50 employees across Managing Partners, an Operating Partner, Principals, Vice Presidents, Associates, a CFO, and finance and operations staff. The legal entity is Biospring Management, LLC, domiciled in New York.
Biospring Partners firmographics
Firmographics- Name
- Biospring Partners
- Legal name
- Biospring Management, LLC
- Website
- https://biospring.com
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Biospring Partners is a New York-based growth buyout firm that invests in technology-enabled, EBITDA-positive pharma services businesses across outsourced biomanufacturing and clinical trial services.
- Ownership category
- akta.pro rank
Biospring Partners industry classification
Industry- Product category
- Private Equity Investment Services
- NAICS
- Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Investment Advice (6282)
- akta.pro primary industry
- Healthcare & Life Sciences Growth Equity (FSANACAB)
- akta.pro secondary industries
- Clinical Operations & Monitoring FSP (CRA/CTM/Start-up) (HLAGAOAA), Regulatory Affairs & Submissions FSP (HLAGAOAD), Laboratory, Bioanalytical & Central Lab Staffing FSP (HLAGAOAI)
Keywords
Where Biospring Partners is headquartered
LocationHeadquarters
- HQ city
- New York
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Biospring Partners business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure
Revenue model
- Private Equity Fund Management: Generates returns through investment in portfolio companies in the pharma services sector. Revenue derived from management fees and carried interest on fund returns.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
Biospring Partners product offering
Product offeringCore offering
Biospring Partners is a private growth buyout firm that invests growth capital in technology-enabled, EBITDA-positive B2B pharma services businesses operating in outsourced complex biomanufacturing (CDMO) and outsourced clinical trial services. The firm combines capital deployment with hands-on operational support through an experienced operating team, deep thematic sector research, and a proprietary sourcing platform.
Product overview
Biospring Partners operates as a private equity firm specializing in growth buyouts of technology-enabled, EBITDA-positive pharma services businesses. The firm's investment strategy focuses on three main themes: Outsourced Complex Biomanufacturing (CDMO), Outsourced Clinical Trial Services, and Digital Transformation. Their portfolio includes Abzena (biologics and ADC manufacturing), Kiniciti (cell and gene therapy services), Cedar Health Research and CenExel (clinical trial site networks), PathAI (AI-powered digital pathology), and Labviva and ixlayer (digital health platforms). The firm provides investment capital along with operational support through a proprietary sourcing platform, thematic research, and an experienced operating team.
Differentiator
Problem solved
Functional benefit
Products and services
- Biospring Partners Investment Services (Growth Buyout Capital for Pharma Services) A private growth buyout service that deploys capital into technology-enabled, EBITDA-positive B2B pharma services businesses in outsourced complex biomanufacturing (CDMO) and outsourced clinical trial services. Combines investment capital with hands-on operational support through an experienced operating team, deep thematic research, and a proprietary sourcing platform. Targets founders, CEOs, and senior management teams of pharma services companies as counterparties.
Companies that use Biospring Partners
Customer profileNamed customers7 records
Segments1 record
Ideal customer profiles2 records
Biospring Partners technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Biospring Partners partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core and minor.
- MabqicoreAbzena (Biospring portfolio company) formed strategic partnership with Mabqi to integrate Mabqi's antibody discovery capabilities with Abzena's development and manufacturing services. Offers biopharma customers streamlined end-to-end drug development solution from discovery through manufacturing.
- Texas Native HealthcoreCedar Health Research (Biospring portfolio company) partnered with Texas Native Health to open an embedded clinical research site within the Dallas nonprofit serving American Indian and Alaska Native communities. Partnership aims to expand access to clinical research for underrepresented populations.
- Eli Lilly and CompanyminorEli Lilly is conducting clinical trials through the Cedar Health Research site at Texas Native Health, addressing conditions disproportionately affecting Native American populations.
- AmgenminorAmgen is conducting clinical trials through the Cedar Health Research site at Texas Native Health, focusing on inclusive clinical research practices.
- SanofiminorSanofi is sponsoring the opening celebration of the Cedar Health Research embedded site at Texas Native Health in February 2026.
- Syneos HealthminorSyneos Health participating in the opening celebration of the Cedar Health Research embedded site at Texas Native Health.
Scale indicators11 records
Recent moves6 records
Expansion highlights6 records
Biospring Partners competitors and assessment
Company assessmentDirect peers
- Linden Capital Partners: Healthcare-only middle-market PE firm with a track record in pharma services, CDMO and life sciences tools. Operates a similar sector-exclusive mandate targeting cash-generative healthcare assets.
- Welsh, Carson, Anderson & Stowe (WCAS): Healthcare-focused growth equity and buyout firm that co-invests with Biospring in Kiniciti and competes for the same EBITDA-positive pharma services assets. Most directly comparable given shared sector focus and joint portfolio activity.
- Avista Capital Partners: Healthcare-dedicated middle-market PE firm investing in pharma services, CDMO, and specialty pharma businesses. Highly comparable investment thesis to Biospring's technology-enabled pharma services strategy.
- Frazier Healthcare Partners: Healthcare-dedicated PE firm investing across pharma services, CDMO, CROs, and specialty pharma. Comparable in its exclusive focus on healthcare and in its growth buyout orientation.
- Ampersand Capital Partners: Middle-market PE firm exclusively focused on life sciences and healthcare tools, services and diagnostics. Directly comparable as a specialist investor in the same pharma services and life science tools vertical.
Broad incumbents
- New Mountain Capital: Large-cap growth PE firm with a deep healthcare services and pharma services franchise (e.g., Real Chemistry, ConcertAI). Comparable in targeting tech-enabled healthcare services businesses but at significantly larger scale.
- GTCR LLC: Established growth-oriented PE firm with a deep healthcare and pharma services franchise (e.g., Cedar Gate, Maravai LifeSciences). Larger and broader than Biospring but competes in the same outsourced pharma services space.
- Bain Capital Life Sciences: Global healthcare PE/venture franchise of Bain Capital investing across pharma services, biopharma, and life sciences tools. Significantly larger scale but competes for many of the same outsourced pharma services assets.
- KKR Health Care Strategic Growth: Growth-oriented healthcare PE strategy within KKR targeting high-growth healthcare services and life sciences businesses. Comparable to Biospring's growth buyout mandate but with materially more capital and brand.
Emerging players
- Health Velocity Capital: Healthcare-only growth equity firm investing in tech-enabled healthcare services and pharma services; a smaller, more venture-oriented peer that overlaps Biospring's digital transformation and clinical trial themes.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Biospring Partners social profiles
Digital presenceBiospring Partners financial estimates
Financial estimateRevenue estimate
Valuation estimate
Biospring Partners leadership team
Management profileNumber of profiles
Profiles14 records
Biospring Partners subsidiaries and ownership
Company hierarchySubsidiaries1 record
Biospring Partners funding detail
Funding detailFunding overview
Funding rounds1 record
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Biospring Partners M&A and investment
M&A and investmentM&A
Investments7 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Biospring Partners
What does Biospring Partners do?
Biospring Partners is a private growth buyout firm that invests growth capital in technology-enabled, EBITDA-positive B2B pharma services businesses operating in outsourced complex biomanufacturing (CDMO) and outsourced clinical trial services. The firm combines capital deployment with hands-on operational support through an experienced operating team, deep thematic sector research, and a proprietary sourcing platform.
Is Biospring Partners a public or private company?
Biospring Partners is a private company. It is classified as private equity controlled and is currently operating.
When was Biospring Partners founded?
Biospring Partners was founded in 2020. It employs 11 to 50 people.
Where is Biospring Partners based?
Biospring Partners is headquartered in New York, United States, in the North America region.
How does Biospring Partners make money?
One revenue line is on record: private Equity Fund Management.
Who are Biospring Partners's main competitors?
Direct peers on record are Linden Capital Partners, Welsh, Carson, Anderson & Stowe (WCAS), Avista Capital Partners, Frazier Healthcare Partners and Ampersand Capital Partners. Broad incumbents are New Mountain Capital, GTCR LLC, Bain Capital Life Sciences and KKR Health Care Strategic Growth. Health Velocity Capital is listed as an emerging player.
Does Biospring Partners have an API?
No public API is recorded for Biospring Partners.
What industry is Biospring Partners in?
Biospring Partners's product category is Private Equity Investment Services. Its primary akta.pro industry code is FSANACAB, Healthcare & Life Sciences Growth Equity, with a secondary code of HLAGAOAA, Clinical Operations & Monitoring FSP (CRA/CTM/Start-up). Its NAICS code is 5417 and its SIC code is 6282.